Web-based Tool for the Dissemination of Evidence-based Interventions for ATOD Prevention

 描述（由申请人提供）：在过去的几十年里，大量的基于证据的治疗计划，酒精，烟草，和其他药物（ATOD）的使用在青年已被严格测试，并显示是有效的。然而，基于证据的ATOD计划（EBP）很少在日常实践中采用，很少以较强的保真度实施，并且往往无法在其预期的服务环境中持续一段时间。越来越多的文献表明，实施质量与EBP嵌入日常实践并实现预期治疗结果的可能性直接相关。NIDA的战略计划明确指出，需要采取有效的方法，帮助缩小ATOD-EBP的发展与其采用和服务环境的长期可持续性之间的差距。该SBIR项目的第二阶段将完成Centervention-ATOD的研究和开发，这是一套可定制的在线工具，专门用于支持任何ATOD-EBP在“真实世界”服务环境中的质量实施和可持续性。在第一阶段，我们开发了Centervention-ATOD原型，主要利益相关者提供了迭代输入;将此技术基础设施应用于基于证据的ATOD预防计划;并评估了原型和拟议可扩展产品的可行性，可用性和价值。利益攸关方表示强烈支持继续研究和开发，并建议扩大产品范围，以包括以干预为重点的方案，以及审查成本效益结果。第二阶段SBIR项目将实现三个具体目标：（1）开发和扩展Centervention-ATOD原型组件，以提高服务设置的可用性和实用性，并将第二个基于证据的ATOD计划集成到技术基础设施中。将评估Centervention-ATOD用于这种新EBP的效用和可用性，并在试点测试之前建议进行修改;（2）通过试点测试评估与传统实施方法相比，Centervention-ATOD是否在提供者实施熟练度和有效性、实施交付质量和EBP结果方面带来额外好处;以及（3）与我们的专家顾问合作，进行正式的成本效益分析，以评估使用Centervention-ATOD实施EBP的货币和非货币成本和收益。没有其他类似的产品是专门设计来帮助ATOD治疗设施实施和维持EBP。Centervention-ATOD将利用3C Institute的技术专长和经验，创建适用于广泛的ATOD-EBP的灵活、可扩展的技术基础设施，降低服务提供商的成本，提高实施质量，并提高项目的可持续性，从而提供巨大的社会效益潜力，并解决大型商业市场。

 DESCRIPTION (provided by applicant): Over the past several decades, a large number of evidence-based treatment programs for alcohol, tobacco, and other drug (ATOD) use in youth have been rigorously tested and shown to be efficacious. Nevertheless, evidence-based ATOD programs (EBPs) are rarely adopted in everyday practice, are seldom implemented with strong fidelity, and often fail to be sustained over time in their intended service settings. A growing body of literature demonstrates implementation quality is directly related to the likelihood an EBP will be embedded into everyday practice and achieve its intended treatment outcomes. NIDA's Strategic Plan specifically identifies the need for effective methods to help close the gap between development of ATOD-EBPs and their adoption and long-term sustainability in service settings. This Phase II SBIR project will complete research and development of Centervention-ATOD, a customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within "real-world" service settings. During Phase I, we developed the Centervention-ATOD prototype with iterative input from key stakeholders; applied this technology infrastructure to an evidence-based ATOD prevention program; and evaluated the feasibility, usability, and value of the prototype and proposed scalable product. Stakeholders voiced strong support for continued research and development and suggested broadening the product's scope to include intervention- focused programs as well as examining cost-effectiveness outcomes. This Phase II SBIR project will accomplish three specific aims: (1) develop and expand Centervention-ATOD prototype components to enhance usability and utility for service settings, and integrate a second evidence-based ATOD program into the technology infrastructure. The utility and usability of Centervention-ATOD for this new EBP will be assessed and recommended modifications incorporated prior to pilot testing; (2) evaluate through pilot testing whether Centervention-ATOD confers additive benefits in provider implementation proficiency and efficacy, quality of implementation delivery, and EBP outcomes compared to traditional implementation methods; and (3) in collaboration with our expert consultant, conduct a formal cost-effectiveness analysis in order to evaluate monetary and non-monetary costs and benefits of implementing EBPs using Centervention-ATOD. No other comparable product exists that is specifically designed to help ATOD treatment facilities implement and sustain EBPs. Centervention-ATOD will leverage 3C Institute's technological expertise and experience to create a flexible, scalable technology infrastructure applicable to ATOD-EBPs on a broad scale, decreasing costs to service providers, enhancing implementation quality, and increasing program sustainability, thereby offering the potential for significant societal benefits and addressing a large, commercial market.